Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies

Wenhuang Feng, Weimin Wang, Ran Meng, Guangyu Wu, Minlu Zhang, Xia Zhang, Huiqiu Yin, Dalong Zhu

ABSTRACT

Introduction This analysis aims to investigate the efficacy and safety of once-daily lixisenatide add-on treatment to basal insulin in Asian individuals with type 2 diabetes, by baseline body mass index (BMI).

Research design and methods Data from all Asian participants in the placebo-controlled GetGoal-Duo 1, GetGoal-L, and GetGoal-L-C Studies were pooled and categorized according to the following BMI subgroups:<25 kg/m², 25 –<30 kg/m² and ≥30 kg/m². Efficacy and safety of lixisenatide versus placebo were evaluated among BMI subgroups. Multivariable regression analyses were also conducted to explore the potential influence of BMI on efficacy outcomes after adjusting for baseline characteristics.

Results 555 participants were included (mean age 53.9 years, 52.4% men). No significant differences in treatment effect between the BMI subgroups were observed for the changes from baseline to 24 weeks in glycated hemoglobin (HbA1c), fasting plasma glucose, postprandial glucose (PPG), PPG excursion, body weight, BMI, and basal insulin dose with lixisenatide, as well as the change in basal insulin dose at study endpoint and the proportion of participants achieving an HbA1c <7% at 24 weeks (all p values for interaction >0.15). In the multivariable regression analysis, participants in the lowest BMI group had a smaller reduction in body weight over the 24-week treatment period relative to the highest BMI group (p=0.023).

Conclusions This post hoc analysis indicates that lixisenatide improved glycemic control regardless of baseline BMI and was well tolerated in Asian individuals unable to achieve their HbA1c target on basal insulin ± oral antidiabetic drugs.

INTRODUCTION

Type 2 diabetes (T2D) is a metabolic disease resulting from insulin resistance and β-cell dysfunction, both of which worsen over time making treatment intensification a therapeutic necessity in almost every individual. Over the past four decades, the worldwide prevalence of T2D has increased...
Emerging technologies, pharmacology and therapeutics

considerably, particularly in developing countries such as China and countries in South-East Asia. This increase in the prevalence of T2D in Asia has been in parallel with a rise in obesity, a known risk factor for T2D, which is thought to be due to the adoption of sedentary lifestyles and energy-dense Western diets. Furthermore, it is typically harder to control blood glucose levels in individuals with T2D who are obese versus those who are not.

There are some differences in the pathogenesis of T2D between Asian and non-Asian individuals. Historically, studies have shown that, compared with non-Asian individuals, T2D in Asian individuals was characterized more by reduced β-cell function than by insulin resistance. However, with the increase in obesity seen in Asia over the last four decades, the influence of insulin resistance in Asian individuals with T2D is rising. The prevalence of obesity in China and other Asian countries is still lower than in the USA and Europe, at any given body mass index (BMI), an Asian person will have more visceral fat, which can be associated with a heightened risk of dysglycemia, than a non-Asian person of the same age and sex. Due to all of these differences, the pathophysiology of T2D in Asian individuals with T2D is now characterized by both more impaired β-cell function and worse insulin resistance than in non-Asian individuals, meaning that more intensive and customized treatment strategies for Asian individuals with T2D are needed.

A high proportion of individuals with T2D require additional treatment within 1–2 years of starting treatment with basal insulin to reach or maintain glycemic targets. When add-on therapy is required for individuals on basal insulin, one recommended option is glucagon-like peptide-1 (GLP-1) receptor agonists. Basal insulin and GLP-1 receptor agonists have complementary mechanisms of action, making the two agents a rational therapeutic combination. While a key mechanism of the GLP-1 receptor agonists is to stimulate insulin secretion from β-cells, the short-acting agents, such as lixisenatide, also slow gastric emptying and suppress appetite and glucagon secretion, which leads to marked reductions in postprandial glucose (PPG). In contrast, basal insulin lowers fasting plasma glucose (FPG).

Studies have shown that adding a GLP-1 receptor agonist is more effective at reducing glycated hemoglobin (HbA1c) levels than increasing the dose of basal insulin, and is associated with a lower incidence of hypoglycemia than adding a rapid-acting insulin or increasing the basal insulin dose. An indirect network meta-analysis of data with different antidiabetic treatments as add-on therapy to basal insulin found that GLP-1 receptor agonists were associated with the greatest HbA1c-lowering effects, and were one of two drug classes (along with sodium-glucose cotransporter-2 inhibitors) associated with the greatest body weight reduction.

The GetGoal clinical study program evaluated the efficacy and safety of lixisenatide as add-on therapy to basal insulin ±oral antidiabetic drugs (OADs) in individuals with T2D and found that, compared with placebo + basal insulin, lixisenatide + basal insulin was consistently associated with a significantly greater reduction in HbA1c and PPG, irrespective of the concomitant OAD regimen. A pooled analysis of data from three similar GetGoal Studies (GetGoal-Duo 1, GetGoal-L and GetGoal-L-C) demonstrated that mean changes in HbA1c with lixisenatide + basal insulin were similar in participants across a range of BMIs. However, given the differences between Asian and non-Asian individuals with T2D and the substantial rise in obesity in Asian countries in the last four decades, it is also important to establish that the efficacy and safety of lixisenatide and basal insulin are consistent across BMI subgroups in Asian people, particularly since lixisenatide is the only GLP-1 receptor antagonist currently approved in China for use with basal insulin. Since the GetGoal Studies included some Asian patients, participants in these studies provided an opportunity to examine the effect of BMI on outcomes with lixisenatide and basal insulin specifically in Asian individuals with T2D. As such, the aim of this post hoc analysis was to investigate the efficacy and safety of lixisenatide and basal insulin according to baseline BMI, using pooled data from the Asian cohorts of participants in GetGoal Duo 1, GetGoal-L, and GetGoal-L-C.

RESEARCH DESIGN AND METHODS
Study designs and participants

This post hoc analysis examined efficacy and safety data obtained from all Asian participants in the intent-to-treat populations of the GetGoal-Duo 1 (ClinicalTrials.gov record: NCT00975286), GetGoal-L (ClinicalTrials.gov record: NCT00715624) and GetGoal-L-C (ClinicalTrials.gov record: NCT01632163) Studies. Full details of the study designs and results for the overall populations have been published previously. Briefly, participants in these randomized, double-blind, placebo-controlled studies had T2D with an HbA1c ≥7% despite basal insulin and other therapies. In GetGoal-Duo 1, lixisenatide or placebo was added to treatment with insulin glargine and metformin ±a sulfonlurea, glinide or thiazolidinedione, whereas in GetGoal-L, participants were receiving lixisenatide or placebo treatment in combination with insulin glargine ±metformin. GetGoal-L-C had the same design as GetGoal-L, but in a predominantly Asian population.

In all three studies, lixisenatide was administered as a once-daily injection starting at a dose of 10 µg. In GetGoal-L and GetGoal-Duo 1, the lixisenatide dose was increased at 1-week intervals, first to 15 µg and then to 20 µg if tolerated. In GetGoal-L-C, the lixisenatide dose was increased to 20 µg after 2 weeks on the starting dose. All participants provided written informed consent.
Efficacy and safety outcomes

The primary endpoint in all three studies was the change in HbA1c from baseline at 24 weeks after randomization. Secondary endpoints included changes from baseline to week 24 in FPG, 2-hour PPG, PPG excursion, body weight, BMI and basal insulin dose. The proportion of individuals achieving an HbA1c <7%, as well as the proportion of individuals achieving a variety of combined endpoints with HbA1c <7%, and no symptomatic hypoglycemia, severe hypoglycemia or gain in body weight, were also assessed.

Safety endpoints included the incidence and frequency of hypoglycemia (severe hypoglycemia, any symptomatic hypoglycemia, and symptomatic hypoglycemia with a blood glucose <3.3 mmol/L), as well as the frequency of gastrointestinal adverse events (nausea, vomiting, and diarrhea).

Statistical analysis

Despite above-mentioned pathophysiology differences in Asian and non-Asian people with T2D, available clinical data do not necessarily indicate a clear BMI cut-off point for all Asians, and as such, the WHO recommends using their internationally recommended BMI classifications in clinical practice. In this analysis, participant-level data were pooled and categorized according to the following BMI subgroups: <25 kg/m², 25 –<30 kg/m² and ≥30 kg/m². These are the internationally used BMI cut-offs, used to define ‘normal weight’, ‘overweight’ and ‘obese’, respectively, which are recommended by the WHO for use in all populations, including those of Asian descent. Descriptive statistics, including mean and SD for continuous variables and number and proportion for categorical variables, were used to summarize participant demographics, clinical characteristics, and efficacy and safety outcomes. Differences between BMI subgroups were tested using a χ² test for categorical variables and t-tests, one-way analysis of variance or Kruskal-Wallis tests for continuous variables. Differences between lixisenatide and placebo within each BMI subgroup were examined using analysis of covariance models for change from baseline to week 24 in HbA1c, FPG, 2-hour PPG, 2-hour PPG excursion, body weight, BMI and basal insulin dose; least squares mean (LSM) and SE for each treatment group and LSM difference (SE, 95% CIs, and p values) between treatment groups were reported. Logistic regression was used to test treatment difference in each BMI subgroup for HbA1c <7% at week 24, and OR, 95% CIs and p values were calculated. The model included a multiplicative interaction term of BMI subgroup×treatment group to assess potential inconsistency in the treatment effect of lixisenatide across BMI subgroups. Covariates in all of the regression analyses included randomization strata of HbA1c (<8%, ≥8%), study (GetGoal-L, GetGoal-L-C, GetGoal-Duo 1), age, gender, and baseline FPG, 2-hour PPG, HbA1c, BMI, basal insulin dose and duration of diabetes.

A two-sided p value of ≤0.05 was considered to be statistically significant. Statistical analyses were performed using SAS V9.3.

RESULTS

Participant characteristics

Of the 1389 participants of the GetGoal-L, GetGoal-L-C and GetGoal-Duo 1 Studies, 555 were Asian and included in this analysis (mean age 53.9 years, 52.4% men). Of these, 183 (33.0%) had a BMI <25 kg/m² at baseline, 276 (49.7%) had a BMI of 25 –<30 kg/m² and 96 (17.3%) had a BMI of ≥30 kg/m². Significant differences in body weight (p<0.001), basal daily insulin dose (units/day; p<0.001), duration of diabetes (p=0.044), gender (p=0.028) and age (p=0.001) were observed between the BMI subgroups (table 1).

Compared with participants of other Asian ethnicities included in this analysis, Chinese participants had significantly higher baseline FPG and PPG levels and body weight, a shorter duration of basal insulin treatment, were receiving a significantly lower basal insulin dose, and had a lower BMI (online supplemental table 1).

Efficacy

No significant differences were found for treatment effect between the BMI subgroups in the changes from baseline in HbA1c, FPG, 2-hour PPG, 2-hour PPG excursion, body weight, BMI, and basal insulin dose to week 24 (all p values for interaction >0.15; table 2, online supplemental table 2).

After 24 weeks of treatment, lixisenatide significantly reduced HbA1c (LSM difference –0.51%; 95% CI –0.68% to –0.33%; p<0.001), 2-hour PPG (LSM difference –3.52 mmol/L; 95% CI –4.31 to –2.73; p<0.001) and 2-hour PPG excursion (LSM difference –3.09 mmol/L; 95% CI –3.81 to –2.38; p<0.001) levels from baseline compared with placebo in the overall cohort (all BMI subgroups combined; table 2). Body weight and BMI were also significantly reduced from baseline with lixisenatide compared with placebo in participants in the lower BMI subgroup (<25 kg/m²: LSM difference –0.96 kg; 95% CI –2.12 to 0.19; p=0.100 and –0.37 kg/m²; 95% CI –0.81 to 0.07; p=0.101, respectively).

FPG was significantly reduced from baseline with lixisenatide compared with placebo in participants in the higher BMI subgroup (≥30 kg/m²: LSM difference –1.21 mmol/L; 95% CI –2.21 to –0.21; p=0.019), but not in the lower BMI subgroups (<25 kg/m²: LSM difference –0.39 mmol/L; 95% CI –1.03 to 0.25; p=0.234; 25 –<30 kg/m²: LSM difference –0.10 mmol/L; 95% CI...
The changes in basal insulin dose (units/day) from baseline to week 24 were significantly different between lixisenatide and placebo recipients in the lower BMI subgroup (<25 kg/m²), but not the higher BMI subgroup (≥30 kg/m²). When assessed by body weight, the changes in basal insulin dose (units/kg/day) from baseline to week 24 were significantly different between lixisenatide and placebo recipients only in the lowest BMI subgroup (<25 kg/m²; online supplemental table 2).

In all BMI subgroups, significantly more participants receiving lixisenatide than participants receiving placebo achieved an HbA1c <7% at week 24 (figure 1). The proportions of participants who achieved an HbA1c <7% ranged between 33.1% and 34.0% with lixisenatide and between 9.5% and 15.0% with placebo across the BMI subgroups. The proportion of participants achieving an HbA1c <7% did not significantly differ between BMI subgroups.

There was a significant difference between BMI subgroups in the proportions of participants who achieved an HbA1c <7% with no symptomatic hypoglycemia with a blood glucose <3.3 mmol/L and no body weight gain (p=0.047; figure 1). In contrast, the proportions of participants who achieved the other evaluated composite endpoints did not significantly differ between BMI subgroups (figure 1). Furthermore, more participants receiving lixisenatide (online supplemental figure 1A) achieved the composite endpoints compared with participants receiving placebo (online supplemental figure 1B).

Safety
No participants in this pooled analysis experienced severe hypoglycemia (table 3). The proportion of participants with any symptomatic hypoglycemia or symptomatic hypoglycemia with a confirmed blood glucose <3.3 mmol/L over the 24-week treatment period was low and similar between the BMI subgroups, with no statistically significant difference observed between the BMI subgroups (p=0.788 and p=0.939 for any symptomatic hypoglycemia and symptomatic hypoglycemia with a blood glucose <3.3 mmol/L, respectively).

The proportion of participants who experienced a gastrointestinal adverse event appeared to be similar between the BMI subgroups. Individuals receiving lixisenatide experienced more gastrointestinal adverse events, such as nausea, vomiting or diarrhea, compared with individuals who received placebo (table 3).

Multivariable regression analysis
After adjusting for baseline characteristics (treatment group, age, gender, FPG, 2-hour PPG, HbA1c, basal insulin dose/body weight and duration of diabetes), participants in the lowest BMI group (<25 kg/m²) relative to the highest BMI group (≥30 kg/m²) had a smaller reduction in body weight over the 24-week treatment period (estimated difference 0.68 kg; 95% CI 0.09 to 1.26; p=0.023; table 4). Participants in the lowest BMI groups (<25 kg/m² and 25−<30 kg/m²) also had a lower basal insulin dose (units/day) at the end of the study relative to BMI ≥30 kg/m².

---

Table 1 Baseline characteristics by baseline body mass index (BMI) subgroup

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>BMI &lt;25 kg/m² (n=42)</th>
<th>LIXI (n=54)</th>
<th>Total (n=96)</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>56.0±9.9</td>
<td>54.3±9.9</td>
<td>55.0±9.9</td>
<td>0.001</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>40 (50.6)</td>
<td>51 (49.0)</td>
<td>91 (49.7)</td>
<td>0.028</td>
</tr>
<tr>
<td>HbA1c, %</td>
<td>7.9±0.7</td>
<td>8.0±0.7</td>
<td>8.0±0.7</td>
<td>0.559</td>
</tr>
<tr>
<td>Duration of diabetes, years</td>
<td>10.6±6.1</td>
<td>11.2±6.6</td>
<td>11.0±6.4</td>
<td>0.044</td>
</tr>
<tr>
<td>Duration of basal insulin, years†</td>
<td>2.3±2.4</td>
<td>2.5±3.0</td>
<td>2.4±2.8</td>
<td>0.577</td>
</tr>
<tr>
<td>FPG, mmol/L</td>
<td>6.8±1.8</td>
<td>7.1±2.3</td>
<td>7.0±2.1</td>
<td>0.921</td>
</tr>
<tr>
<td>2-hour PPG, mmol/L</td>
<td>14.1±3.4</td>
<td>14.7±4.9</td>
<td>14.4±4.3</td>
<td>0.143</td>
</tr>
<tr>
<td>Basal insulin dose, U/day</td>
<td>30.7±11.6</td>
<td>33.3±13.5</td>
<td>32.2±12.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Basal insulin dose, U/day/kg</td>
<td>0.5±0.2</td>
<td>0.6±0.2</td>
<td>0.5±0.2</td>
<td>0.154</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>23.0±1.3</td>
<td>23.2±1.3</td>
<td>23.2±1.3</td>
<td>0.044</td>
</tr>
<tr>
<td>Body weight, kg</td>
<td>61.9±7.4</td>
<td>61.6±7.4</td>
<td>61.7±7.4</td>
<td>0.114</td>
</tr>
</tbody>
</table>

All values are given as mean±SD unless otherwise stated.
*P value for differences between total participants of the different BMI subgroups.
†Only available for GetGoal-L and GetGoal-L C Studies.
FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; LIXI, lixisenatide; PBO, placebo; PPG, postprandial glucose.

---

~0.65 to 0.46; p=0.731) or overall study population (LSM difference −0.94; 95% CI −0.72 to 0.03; p=0.074; table 2).

Emerging technologies, pharmacology and therapeutics
Table 2  Clinical responses to lixisenatide (LIXI) or placebo (PBO) add-on treatment to basal insulin therapy±oral antidiabetic drugs in the overall pooled population and by baseline body mass index (BMI) subgroup

<table>
<thead>
<tr>
<th>BMI category</th>
<th>HbA1c, %</th>
<th>FPG, mmol/L</th>
<th>2-hour PPG, mmol/L</th>
<th>2-hour PPG excursion, mmol/L</th>
<th>Body weight, kg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Interaction</td>
<td>P value</td>
<td>Interaction</td>
<td>P value</td>
<td>Interaction</td>
</tr>
<tr>
<td>PBO (n=79)</td>
<td>LIXI (n=104)</td>
<td></td>
<td>PBO (n=142)</td>
<td>LIXI (n=134)</td>
<td></td>
</tr>
<tr>
<td>BMI &lt;25kg/m²</td>
<td>Mean±SD at baseline</td>
<td></td>
<td>Mean±SD at week 24</td>
<td></td>
<td>Mean±SD change from baseline</td>
</tr>
<tr>
<td></td>
<td>7.89±0.67</td>
<td>8.00±0.73</td>
<td>7.97±0.72</td>
<td>8.01±0.78</td>
<td>8.10±0.84</td>
</tr>
<tr>
<td></td>
<td>8.08±1.20</td>
<td>7.57±1.09</td>
<td>7.88±0.98</td>
<td>7.57±1.28</td>
<td>8.21±1.24</td>
</tr>
<tr>
<td></td>
<td>0.29±0.14</td>
<td>-0.33±0.13</td>
<td>-0.11±0.12</td>
<td>-0.53±0.11</td>
<td>-0.04±0.19</td>
</tr>
<tr>
<td></td>
<td>&lt;0.001</td>
<td>0.001</td>
<td>0.013</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11.4</td>
<td>33.3</td>
<td>15.0</td>
<td>33.1</td>
<td>9.5</td>
</tr>
<tr>
<td></td>
<td>21.9±5.9</td>
<td>18.1±5.2</td>
<td>24.4±7.9</td>
<td>20.3±5.5</td>
<td>0.58±0.17</td>
</tr>
<tr>
<td></td>
<td>5.98 ±2.24±15.97</td>
<td>4.71±1.20±18.51</td>
<td>4.35±2.66±7.12</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>0.027</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>BMI 25&lt;30kg/m²</td>
<td>Mean±SD at baseline</td>
<td></td>
<td>Mean±SD at week 24</td>
<td></td>
<td>Mean±SD change from baseline</td>
</tr>
<tr>
<td></td>
<td>8.1±0.67</td>
<td>7.49±2.23</td>
<td>7.92±2.13</td>
<td>7.32±2.83</td>
<td>8.60±2.55</td>
</tr>
<tr>
<td></td>
<td>0.45±0.30</td>
<td>0.06±0.27</td>
<td>0.57±0.26</td>
<td>0.48±0.25</td>
<td>1.09±0.42</td>
</tr>
<tr>
<td></td>
<td>&lt;0.001</td>
<td>0.001</td>
<td>0.013</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>34 (33.3)</td>
<td>34 (33.3)</td>
<td>21 (15.0)</td>
<td>42 (33.1)</td>
<td>4 (9.5)</td>
</tr>
<tr>
<td></td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>0.027</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>BMI ≥30kg/m²</td>
<td>Mean±SD at baseline</td>
<td></td>
<td>Mean±SD at week 24</td>
<td></td>
<td>Mean±SD change from baseline</td>
</tr>
<tr>
<td></td>
<td>9.1±0.67</td>
<td>7.49±2.23</td>
<td>7.92±2.13</td>
<td>7.32±2.83</td>
<td>8.60±2.55</td>
</tr>
<tr>
<td></td>
<td>0.45±0.30</td>
<td>0.06±0.27</td>
<td>0.57±0.26</td>
<td>0.48±0.25</td>
<td>1.09±0.42</td>
</tr>
<tr>
<td></td>
<td>&lt;0.001</td>
<td>0.001</td>
<td>0.013</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>21 (15.0)</td>
<td>42 (33.1)</td>
<td>4 (9.5)</td>
<td>18 (34.0)</td>
<td>34 (13.0)</td>
</tr>
<tr>
<td></td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>0.027</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>All pooled participants</td>
<td>Mean±SD at baseline</td>
<td></td>
<td>Mean±SD at week 24</td>
<td></td>
<td>Mean±SD change from baseline</td>
</tr>
<tr>
<td></td>
<td>7.97±0.67</td>
<td>7.49±2.23</td>
<td>7.92±2.13</td>
<td>7.32±2.83</td>
<td>8.60±2.55</td>
</tr>
<tr>
<td></td>
<td>0.45±0.30</td>
<td>0.06±0.27</td>
<td>0.57±0.26</td>
<td>0.48±0.25</td>
<td>1.09±0.42</td>
</tr>
<tr>
<td></td>
<td>&lt;0.001</td>
<td>0.001</td>
<td>0.013</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>21 (15.0)</td>
<td>42 (33.1)</td>
<td>4 (9.5)</td>
<td>18 (34.0)</td>
<td>34 (13.0)</td>
</tr>
<tr>
<td></td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>0.027</td>
<td>&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>

Continued
Emerging technologies, pharmacology and therapeutics

the highest BMI group (≥30 kg/m²; estimated difference both p<0.001). However, there was no significant difference among the different BMI subgroups in the change in basal insulin dose from baseline to week 24. Changes in HbA1c, FPG, and 2-hour PPG from baseline to week 24 were not significantly different among the different BMI subgroups. Also, the likelihood of achieving an HbA1c <7% was similar among the different BMI subgroups. Finally, participants in the lowest BMI subgroup (<25 kg/m²) had a lower likelihood of achieving an HbA1c <7% with no body weight gain (OR 0.40; 95% CI 0.18 to 0.90; p=0.005) relative to the highest BMI subgroup (≥30 kg/m²; table 4).

DISCUSSION

The results of this pooled post hoc analysis demonstrate that, regardless of baseline BMI, lixisenatide was beneficial as add-on treatment to basal insulin therapy ±OADs in Asian individuals with T2D. No significant differences were observed between the BMI subgroups in the changes from baseline in HbA1c, FPG, 2-hour PPG from baseline to week 24. The proportion of participants with hypoglycemia was low and similar between the BMI subgroups. As expected, lixisenatide significantly reduced HbA1c, 2-hour PPG and PPG excursion levels from baseline at week 24 compared with placebo in all BMI subgroups. Furthermore, in all BMI subgroups, significantly more participants receiving lixisenatide than participants receiving placebo achieved an HbA1c <7%. Finally, participants receiving lixisenatide experienced more gastrointestinal adverse events than those receiving placebo, with little difference seen between the BMI subgroups.

In the original publications of GetGoal-Duo 1, GetGoal-L and GetGoal-L-C, lixisenatide as add-on therapy to insulin ±OADs was associated with significantly greater reductions in HbA1c and PPG compared with placebo in individuals with T2D. Eto et al

Figure 1  Proportion of all study participants achieving the composite endpoints by baseline body mass index (BMI) subgroup. *P=0.047. BG, blood glucose; HbA1c, glycated hemoglobin.

Table 2 Continued

<table>
<thead>
<tr>
<th>Group</th>
<th>BMI, kg/m²</th>
<th>PBO (n=263)</th>
<th>LSM±SE change from baseline</th>
<th>LSM difference (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI &lt;25 kg/m²</td>
<td>23.07±1.24</td>
<td>0.22±0.09</td>
<td>0.34 (±0.54 to 0.15)</td>
<td>&lt;0.001</td>
<td>P value</td>
</tr>
<tr>
<td>BMI 25–&lt;30 kg/m²</td>
<td>23.22±1.31</td>
<td>0.34 (±0.54 to 0.15)</td>
<td>&lt;0.001</td>
<td>P value</td>
<td></td>
</tr>
<tr>
<td>BMI ≥30 kg/m²</td>
<td>27.13±1.40</td>
<td>0.36±0.10</td>
<td>0.13±0.19</td>
<td>0.101</td>
<td></td>
</tr>
</tbody>
</table>

FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; LSM, least squares mean; PPG, postprandial glucose.
Emerging technologies, pharmacology and therapeutics

found that the mean reductions in HbA1c were smaller, but not significantly so, for participants enrolled in these studies with a lower BMI relative to those with a higher BMI (mean changes between −0.63% and −0.73%; p=0.88 between BMI groups). In contrast, they also found that the mean reductions in PPG with lixisenatide were greater in participants with a lower BMI than those with a higher BMI (p<0.0001 between BMI groups). The results of this analysis showed that, in the Asian participants of these studies, there were no significant differences in the changes from baseline observed in HbA1c and 2-hour PPG between BMI subgroups, suggesting that the difference observed between BMI subgroups in PPG in the analysis by Eto et al might be driven by the non-Asian participants of the studies. The results of this analysis are also in line with another pooled analysis of eight studies in the GetGoal study program, which indicated that baseline BMI had little effect on the change in HbA1c observed with lixisenatide.

In the overall pooled population and the lower BMI subgroups, lixisenatide had little to no effect on FPG compared with placebo. This was an expected result, as participants enrolled in the GetGoal Studies had controlled FPG levels prior to initiating the add-on treatment and shorter acting GLP-1 receptor agonists are known to primarily reduce PPG and not FPG. However, studies have shown that in individuals receiving basal insulin who are not achieving HbA1c targets,

**Table 3** Hypoglycemia and gastrointestinal adverse events by baseline body mass index (BMI) subgroup

<table>
<thead>
<tr>
<th>BMI &lt;25kg/m²</th>
<th>BMI 25−&lt;30kg/m²</th>
<th>BMI ≥30kg/m²</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBO (n=79)</td>
<td>LIXI (n=104)</td>
<td>Total (n=183)</td>
</tr>
<tr>
<td>No of events/ patient-year</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Severe hypoglycemia n (%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Any symptomatic hypoglycemia n (%)</td>
<td>8 (10.1)</td>
<td>17 (16.4)</td>
</tr>
<tr>
<td>No of events/ patient-year</td>
<td>23 (16.2)</td>
<td>19 (14.2)</td>
</tr>
<tr>
<td>Gastrointestinal adverse events, n (%)</td>
<td>13 (16.5)</td>
<td>42 (40.4)</td>
</tr>
<tr>
<td>Nausea</td>
<td>4 (5.1)</td>
<td>30 (28.9)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>2 (2.5)</td>
<td>12 (11.5)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3 (3.8)</td>
<td>4 (3.9)</td>
</tr>
</tbody>
</table>

BG, blood glucose; LIXI, lixisenatide; PBO, placebo.

**Table 4** Summary of multivariable regression results of the association of body mass index (BMI) subgroup with different clinical responses in Asian participants with type 2 diabetes

<table>
<thead>
<tr>
<th>BMI &lt;25 vs ≥30kg/m²</th>
<th>BMI 25−&lt;30 vs ≥30kg/m²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estimated difference (95% CI)</td>
<td>P value</td>
</tr>
<tr>
<td>Change in HbA1c, %</td>
<td>0.18 (−0.09 to 0.44)</td>
</tr>
<tr>
<td>Change in FPG, mmol/L</td>
<td>−0.26 (−0.83 to 0.30)</td>
</tr>
<tr>
<td>Change in 2-hour PPG, mmol/L</td>
<td>0.47 (−0.74 to 1.67)</td>
</tr>
<tr>
<td>Change in body weight, kg</td>
<td>0.68 (0.09 to 1.26)</td>
</tr>
<tr>
<td>Change in basal insulin dose, U/day</td>
<td>0.48 (−1.20 to 2.15)</td>
</tr>
<tr>
<td>Endpoint basal insulin dose, U/day</td>
<td>−13.95 (−16.14 to 11.76)</td>
</tr>
<tr>
<td>Change in basal insulin dose, U/kg/day</td>
<td>0.007 (−0.018 to 0.032)</td>
</tr>
<tr>
<td>Endpoint basal insulin dose, U/kg/day</td>
<td>0.007 (−0.018 to 0.032)</td>
</tr>
<tr>
<td>OR (95% CI)</td>
<td>P value</td>
</tr>
<tr>
<td>Endpoint HbA1c &lt;7%</td>
<td>0.97 (0.48 to 1.93)</td>
</tr>
<tr>
<td>Endpoint HbA1c &lt;7% and no body weight gain</td>
<td>0.40 (0.18 to 0.90)</td>
</tr>
</tbody>
</table>

FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; PPG, postprandial glucose.
targeting PPG over FPG is critical as, while both HbA1c is
an indication of blood glucose exposure from a combina-
tion of both PPG and FPG, PPG is the main contributor
to hyperglycemic exposure in these individuals.37 Inter-
estingly, in the current analysis, lixisenatide significantly
reduced FPG compared with placebo in those individuals
with a BMI ≥20 kg/m². This was not observed by Eto et al. in
the pooled analysis of the study populations,35 suggesting
that BMI may influence the effect of lixisenatide on FPG
levels in the Asian versus non-Asian participants of the
GetGoal Studies. However, it is important to highlight
that this result may be due to the small sample sizes and
with no p value for interaction between BMI subgroups
found for FPG, further studies are warranted to confirm
this result in those individuals with a BMI ≥30 kg/m².

Like other GLP-1 receptor agonists, lixisenatide
promotes body weight loss in individuals with T2D.38 In
this analysis, a modest mean reduction in body weight
of 0.61 kg over 24 weeks was observed in individuals
receiving lixisenatide, compared with an increase of 0.39 kg
in placebo recipients. Lixisenatide was associ-
ated with a significantly greater reduction in body weight
versus placebo in individuals with a BMI <25 kg/m² or a
BMI of 25–30 kg/m² (both p <0.001) but not in indi-
viduals with a BMI ≥30 kg/m² (p =0.100 vs placebo).
This result is contradictory to that observed by Eto et al,
where a greater baseline BMI tended to be associated
with a greater reduction in body weight with lixisenatide
add-on treatment.33 There may be a number of reasons
for this unexpected result in the current analysis. First,
the increase in body weight observed in individuals
receiving placebo with a BMI ≥30 kg/m² was smaller than
that observed in individuals in the lower BMI subgroups
receiving placebo. Second, the group with a BMI ≥30 kg/m²
comprised only 17% of the total study cohort, so the
analysis may have been underpowered to detect a differ-
ce in body weight loss between lixisenatide and placebo
in this group. The latter reason is supported by the fact
that the reduction in body weight with lixisenatide in
participants with a BMI ≥30 kg/m² was similar to that
observed in participants with a BMI of 25–30 kg/m².

Because of their beneficial effects on weight loss, clinical
studies of GLP-1 receptor agonists are often enriched
with individuals whose BMIs are in the overweight or
obese categories. Moreover, average weight and height
differ between ethnic groups, so the BMI thresholds that
define overweight/obesity in a Caucasian population
are not necessarily applicable in Asian individuals.38 The
current study demonstrates that lixisenatide as add-on
therapy to basal insulin is effective in an Asian popula-
tion, irrespective of BMI, and confirms previous data that
lixisenatide efficacy is independent of BMI from studies
in Caucasian or Japanese individuals with diabetes.40–42

The results of this analysis are in line with other analyses
conducted in individuals receiving other GLP-1 receptor
agonists. Studies of both liraglutide43 44 and exenatide45–49
indicate that baseline BMI values are not predictive of
the reduction in HbA1c seen with these treatments. While
Fadini et al reported that baseline BMI was predictive for
the reduction in body weight observed with liraglutide
treatment,43 none of the other studies of GLP-1 receptor
agonists found a correlation between baseline BMI and
body weight loss.44–49

There are some limitations to this analysis, the main
one being the post hoc nature of this analysis. While
the retrospective design and imbalance in participant
numbers between subgroups limit the internal validity of
these results, the results indicate that BMI does not appear
to have an effect on the known effectiveness and safety
of lixisenatide in Asian individuals with T2D. Further
prospective studies evaluating the effect of lixisenatide
and other GLP-1 receptor agonists in participants with
different BMIs are warranted to confirm these results.
Another limitation of this analysis may be the BMI catego-
ries chosen, as studies have suggested that individuals of
Asian descent have different health risks associated with
BMI compared with those of European descent. However,
a WHO expert consultation addressed these issues in the
early 2000s, concluding that the WHO BMI cut-off points
should be retained as international classifications for all
populations,44 and as such the standard BMI categories
were assessed in this analysis. However, further studies
investigating the effects of different BMI/waist circum-
ference or precise adipose tissue measurement on the effi-
cacy and tolerability of lixisenatide are warranted. Finally,
given the design of the original GetGoal Studies, we were
unable to determine the true effect of lixisenatide +basal
insulin treatment on FPG, or if BMI had any influence on
the glucose-lowering effect of this combination, as during
the run-in period basal insulin treatment was titrated to
achieve optimal FPG levels. Again, a study investigating
lixisenatide +basal insulin in individuals with elevated
FPG levels, as well as the influence of BMI on the treat-
ment effect, is warranted.

CONCLUSION

The findings of this post hoc analysis indicate that BMI
does not impact on the ability of lixisenatide to opti-
mize glycemic control in Asian individuals with T2D
unable to achieve their HbA1c glycemic targets on basal
insulin ±OADs. In clinical practice, there is a large diver-
sity in the BMI profiles of Asian individuals receiving
basal insulin who require additional treatment, so this
favorable effect of lixisenatide on glycemic control, inde-
dependent of BMI, is promising and supports the combi-
nation of basal insulin +lixisenatide in these individuals.

Author affiliations
1Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University
Medical School, Nanjing, China
2Department of Medical Affairs, Sanofi, Shanghai, China

Acknowledgements We thank the participants, investigators, and their staff
for participating in the study. We would also like to thank Simone Tait of Springer
Healthcare Communications who wrote the outline and first draft of this article.
This medical writing assistance was funded by Sanofi Aventis.
Contributors DZ, XZ and HY designed the study. WW was involved in data acquisition. MZ performed the statistical analysis. WF, RM and GW were involved in drafting the manuscript and DZ, WW, and XZ critically revised the manuscript. All authors read and approved the final manuscript.

Funding The GetGoal Studies and this post hoc analysis were supported by Sanofi. Assistance for the development of this article, as well as the article processing fee, was funded by Sanofi.

Competing interests WF, WW, RM and DZ declare no conflict of interest. GW, MZ, XZ and HY are employees of Sanofi China.

Patient consent for publication Not required.

Ethics approval The data in this study were derived from previous clinical trials. The Ethics Committees and Institutional Boards of those studies are detailed in the original publications. All procedures performed in those studies were in accordance with the authors’ institutions’ ethical recommendations and with the 1964 Helsinki Declaration and its later amendments.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Qualified researchers may request access to patient-level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient-level data will be anonymized, and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi’s data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudiedat arequest.com.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Dalong Zhu http://orcid.org/0000-0002-1064-1261

REFERENCES


31. Seino Y, Min KW, Niemoeller E, et al. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-A); Diabetes Obes Metab 2012;14:140–50.

Emerging technologies, pharmacology and therapeutics


33 Eto K, Naito Y, Seino Y. Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials. Diabetol Metab Syndr 2015;7:106.


## Supplementary information

### Supplementary Table 1. Baseline characteristics by ethnicity.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Chinese</th>
<th>Other Asian</th>
<th>All pooled participants</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PBO</td>
<td>LIXI</td>
<td>Total</td>
<td>PBO</td>
</tr>
<tr>
<td></td>
<td>(n = 129)</td>
<td>(n = 122)</td>
<td>(n = 251)</td>
<td>(n = 134)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>55.3 ± 9.2</td>
<td>53.5 ± 9.4</td>
<td>54.4 ± 9.4</td>
<td>53.8 ± 9.4</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>72 (55.8)</td>
<td>71 (58.2)</td>
<td>143 (57.0)</td>
<td>67 (50.0)</td>
</tr>
<tr>
<td>HbA1c, %</td>
<td>8.0 ± 0.7</td>
<td>7.9 ± 0.7</td>
<td>8.0 ± 0.7</td>
<td>8.0 ± 0.7</td>
</tr>
<tr>
<td>Duration of diabetes, years</td>
<td>9.2 ± 5.3</td>
<td>9.5 ± 5.4</td>
<td>9.4 ± 5.4</td>
<td>9.1 ± 7.0</td>
</tr>
<tr>
<td>Duration of basal insulin, yearsa</td>
<td>2.0 ± 2.1</td>
<td>1.9 ± 2.2</td>
<td>1.9 ± 2.2</td>
<td>2.7 ± 2.8</td>
</tr>
<tr>
<td>FPG, mmol/L</td>
<td>7.4 ± 1.5</td>
<td>7.5 ± 1.9</td>
<td>7.4 ± 1.7</td>
<td>6.3 ± 2.0</td>
</tr>
<tr>
<td>2-hour PPG, mmol/L</td>
<td>15.8 ± 3.3</td>
<td>15.4 ± 3.9</td>
<td>15.6 ± 3.6</td>
<td>12.4 ± 3.4</td>
</tr>
<tr>
<td>Basal insulin dose, U/day</td>
<td>30.8 ± 10.5</td>
<td>29.0 ± 10.5</td>
<td>29.9 ± 10.5</td>
<td>45.2 ± 22.6</td>
</tr>
<tr>
<td>Basal insulin dose, U/day/kg</td>
<td>0.4 ± 0.2</td>
<td>0.4 ± 0.1</td>
<td>0.4 ± 0.1</td>
<td>0.6 ± 0.3</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>26.6 ± 3.3</td>
<td>26.2 ± 3.3</td>
<td>26.4 ± 3.3</td>
<td>27.5 ± 4.1</td>
</tr>
<tr>
<td>Body weight, kg</td>
<td>73.6 ± 12.3</td>
<td>73.0 ± 13.4</td>
<td>73.3 ± 12.8</td>
<td>71.0 ± 13.4</td>
</tr>
</tbody>
</table>

All values are given as mean ± standard deviation unless otherwise stated.

*a Only available for GetGoal-L and GetGoal-L-C studies.

BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; LIXI, lixisenatide; PBO, placebo; PPG, postprandial glucose; U, units.
**Supplementary Table 2.** Change in basal insulin dose with lixisenatide or placebo add-on treatment to basal insulin therapy ± oral antidiabetic drugs in the overall pooled population and by baseline body mass index subgroup.

<table>
<thead>
<tr>
<th>BMI &lt; 25 kg/m²</th>
<th>BMI 25 to &lt; 30 kg/m²</th>
<th>BMI ≥ 30 kg/m²</th>
<th>All pooled participants</th>
<th>Interaction P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PBO</td>
<td>LIXI</td>
<td>PBO</td>
<td>LIXI</td>
</tr>
<tr>
<td>(n = 79)</td>
<td>(n = 104)</td>
<td>(n = 142)</td>
<td>(n = 42)</td>
<td>(n = 54)</td>
</tr>
<tr>
<td><strong>Basal insulin dose, U/day</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD at baseline</td>
<td>30.98 ± 11.62</td>
<td>33.19 ± 13.02</td>
<td>38.30 ± 15.19</td>
<td>37.34 ± 16.36</td>
</tr>
<tr>
<td>Mean ± SD at week 24</td>
<td>31.98 ± 12.75</td>
<td>31.25 ± 12.57</td>
<td>38.36 ± 16.20</td>
<td>36.57 ± 16.47</td>
</tr>
<tr>
<td>LSM ± SE change from baseline</td>
<td>1.71 ± 0.90</td>
<td>–1.20 ± 0.82</td>
<td>1.46 ± 0.66</td>
<td>–0.06 ± 0.63</td>
</tr>
<tr>
<td>LSM difference (95% CI)</td>
<td>–2.91 (–4.85, –0.97)</td>
<td>–1.53 (–2.94, –0.11)</td>
<td>–1.70 (–4.43, 1.03)</td>
<td>–2.12 (–3.15, –1.09)</td>
</tr>
<tr>
<td>P-value</td>
<td>0.004</td>
<td>0.035</td>
<td>0.219</td>
<td></td>
</tr>
<tr>
<td><strong>Basal insulin dose, U/day/kg</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD at baseline</td>
<td>0.51 ± 0.20</td>
<td>0.54 ± 0.22</td>
<td>0.54 ± 0.23</td>
<td>0.52 ± 0.24</td>
</tr>
<tr>
<td>Mean ± SD at week 24</td>
<td>0.52 ± 0.22</td>
<td>0.52 ± 0.22</td>
<td>0.54 ± 0.24</td>
<td>0.51 ± 0.25</td>
</tr>
<tr>
<td>LSM ± SE change from baseline</td>
<td>0.02 ± 0.01</td>
<td>–0.02 ± 0.01</td>
<td>0.02 ± 0.01</td>
<td>0.01 ± 0.01</td>
</tr>
<tr>
<td>LSM difference (95% CI)</td>
<td>–0.04 (–0.07, –0.01)</td>
<td>–0.02 (–0.04, 0.01)</td>
<td>–0.01 (–0.05, 0.02)</td>
<td>–0.02 (–0.04, –0.01)</td>
</tr>
<tr>
<td>P-value</td>
<td>0.014</td>
<td>0.176</td>
<td>0.353</td>
<td>0.002</td>
</tr>
</tbody>
</table>

CI, confidence interval; LIXI, lixisenatide; LSM, least squares mean; PBO, placebo; SD, standard deviation; SE, standard error; U, units.
**Supplementary Figure 1.** Proportion of participants receiving (A) lixisenatide and (B) placebo achieving the composite endpoints by baseline body mass index subgroup. BG, blood glucose; BMI, body mass index; HbA1c, glycated haemoglobin.